EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are among the front-line agents used for EGFR-mutant NSCLC, and several first-, second-, and third-generation EGFR-TKIs have been developed, starting from gefitinib (7, 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.